Portal de Periódicos da CAPES

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation

2018; Elsevier BV; Volume: 6; Issue: 1 Linguagem: Inglês

10.1016/j.jaip.2017.11.023

2213-2201

Katie D. White, Riichiro Abe, Michael R. Ardern‐Jones, Thomas M. Beachkofsky, Charles S. Bouchard, Bruce Carleton, James Chodosh, Ricardo Cibotti, Robert L. Davis, Joshua C. Denny, Roni P. Dodiuk‐Gad, Elizabeth N. Ergen, Jennifer Goldman, James H. Holmes, Wen‐Hung Chung, Mario E. Lacouture, Rannakoe Lehloenya, S. Mallal, Teri A. Manolio, Robert G. Micheletti, Caroline M. Mitchell, Maja Mockenhaupt, David A. Ostrov, Rebecca Pavlos, Munir Pirmohamed, Elena Pope, Alec Redwood, Misha Rosenbach, Michael Rosenblum, Jean-Claude Roujeau, Arturo P. Saavedra, Hajirah N. Saeed, Jeffery P. Struewing, Hirohiko Sueki, Chonlaphat Sukasem, Cynthia Sung, Jason A. Trubiano, Jessica Weintraub, Lisa M. Wheatley, Kristina Williams, Brandon Worley, Wen‐Hung Chung, Neil H. Shear, Elizabeth J. Phillips,

Pharmaceutical industry and healthcare

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN. Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN. Information for Category 1 CME CreditCredit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI: In Practice Web site: www.jaci-inpractice.org/. The accompanying tests may only be submitted online at www.jaci-inpractice.org/. Fax or other copies will not be accepted.Date of Original Release: January 1, 2018. Credit may be obtained for these courses until December 31, 2018.Copyright Statement: Copyright © 2018-2020. All rights reserved.Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.Target Audience: Physicians and researchers within the field of allergic disease.Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.List of Design Committee Members: Katie D. White, MD, PhD, Riichiro Abe, MD, PhD, Michael Ardern-Jones, DPhil, FRCP, Thomas Beachkofsky, MD, Charles Bouchard, MD, MA, Bruce Carleton, PharmD, James Chodosh, MD, MPH, Ricardo Cibotti, PhD, Robert Davis, MD, MPH, Joshua C. Denny, MD, MS, Roni P. Dodiuk-Gad, MD, Elizabeth N. Ergen, MD, Jennifer L. Goldman, MD, MS, James H. Holmes IV, MD, FACS, Shuen-Iu Hung, PhD, Mario E. Lacouture, MD, Rannakoe J. Lehloenya, MBChB, FCDerm (SA), Simon Mallal, MBBS, Teri A. Manolio, MD, PhD, Robert G. Micheletti, MD, Caroline M. Mitchell, MD, MPH, Maja Mockenhaupt, MD, David A. Ostrov, PhD, Rebecca Pavlos, PhD, Munir Pirmohamed, MB ChB (Hons), PhD, Elena Pope, MD, MSc, FRCPC, Alec Redwood, PhD, Misha Rosenbach, MD, Michael D. Rosenblum, MD, PhD, Jean-Claude Roujeau, MD, Arturo P. Saavedra, MD, PhD, MBA, Hajirah N. Saeed, MD, Jeffery P. Struewing, MD, Hirohiko Sueki, MD, Chonlaphat Sukasem, BPharm, PhD, Cynthia Sung, PhD, FCP, Jason A. Trubiano, MD, Jessica Weintraub, PharmD, BCPS, Lisa M. Wheatley, MD, MPH, Kristina B. Williams, RN, BSN, Brandon Worley, MD, MSc, Wen-Hung Chung, MD, PhD, Neil H. Shear, MD, and Elizabeth J. Phillips, MD (authors); Michael Schatz, MD, MS (editor)Learning objectives:1.To identify current knowledge gaps in the clinical management of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).2.To identify key research questions and gaps pertinent to SJS/TEN.3.To discuss advances in knowledge of the genetic and mechanistic basis of SJS/TEN and their translational outputs such as pharmacogenomic screening.Recognition of Commercial Support: This CME has not received external commercial support.Disclosure of Relevant Financial Relationships with Commercial Interests: K. D. White has received research support from the National Institutes of Health (NIH). T. Beachkofsky is an Active Duty Officer in the United States Air Force. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Air Force, the Department of Defense, nor the US government. B. Carleton has received research support from the Canadian Institutes of Health Research, Canada Foundation for Innovation, Genome Canada Genome Columbia, and Provincial Health Services Authority and has received consultancy fees from AEVI Genomic Medicine. J. H. Holmes IV has stocks in Abbott Labs, Abbvie, and PermeaDerm, Inc. M. E. Lacouture has received support from Genentech and Roche. S. Mallal has Equity in IIID Ltd that holds patents for HLA-B*57:01 screening for abacavir hypersensitivity. C. M. Mitchell has received personal fees from Symbiomix Therapeutics Inc. M. Mockenhaupt has received research support from Boehringer Ingelheim, Sanofi-Aventis, Tibotec-Janssen, Grünenthal, UCB-Pharma, and BIAL; has received personal fees from Pfizer and Merck; receives royalties from UpToDate; and has served as an expert witness in legal cases of Stevens-Johnson syndrome/toxic epidermal necrolysis in the United States (last July 2016). M. Pirmohamed has received research support from the UK Medical Research Council and the International Serious Adverse Event Consortium. E. Pope has received consultancy fees from Abvvie and ProQI; has received research support from Galderma; and has received consultancy fees and research support from Pierre Fabre Pharmaceuticals. J.-C. Roujeau has received personal fees from Ipsen Menarini, Pfizer, Novartis, Clinigen, Ab-Science, and UpToDate and has been a paid expert witness for US lawyers in several cases of SJS/TEN (more than 36 months ago). H. Sueki has received research support from the Ministry of Health, Labor and Welfare of Japan. K. B. Williams has received research support from the NIH. N. H. Shear has received research support from Lilly Canada and the NIH; has received speaker fees from Takeda; and is an unpaid board member of the Canadian Stevens-Johnson Foundation. E. J. Phillips has received research support from the National Health and Medical Research Council Australia, the NIH, and ACH2 Australia; receives royalties from UpToDate; has received consultancy fees from Biocryst, Aicuris, Xcovery, and Medicines for Malaria (MMV); and is codirector of the company holding the patent for HLA-B*57:01 testing for abacavir hypersensitivity reaction. The rest of the authors declare that they have no relevant conflicts of interest. M. Schatz disclosed no relevant financial relationships. Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI: In Practice Web site: www.jaci-inpractice.org/. The accompanying tests may only be submitted online at www.jaci-inpractice.org/. Fax or other copies will not be accepted. Date of Original Release: January 1, 2018. Credit may be obtained for these courses until December 31, 2018. Copyright Statement: Copyright © 2018-2020. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. List of Design Committee Members: Katie D. White, MD, PhD, Riichiro Abe, MD, PhD, Michael Ardern-Jones, DPhil, FRCP, Thomas Beachkofsky, MD, Charles Bouchard, MD, MA, Bruce Carleton, PharmD, James Chodosh, MD, MPH, Ricardo Cibotti, PhD, Robert Davis, MD, MPH, Joshua C. Denny, MD, MS, Roni P. Dodiuk-Gad, MD, Elizabeth N. Ergen, MD, Jennifer L. Goldman, MD, MS, James H. Holmes IV, MD, FACS, Shuen-Iu Hung, PhD, Mario E. Lacouture, MD, Rannakoe J. Lehloenya, MBChB, FCDerm (SA), Simon Mallal, MBBS, Teri A. Manolio, MD, PhD, Robert G. Micheletti, MD, Caroline M. Mitchell, MD, MPH, Maja Mockenhaupt, MD, David A. Ostrov, PhD, Rebecca Pavlos, PhD, Munir Pirmohamed, MB ChB (Hons), PhD, Elena Pope, MD, MSc, FRCPC, Alec Redwood, PhD, Misha Rosenbach, MD, Michael D. Rosenblum, MD, PhD, Jean-Claude Roujeau, MD, Arturo P. Saavedra, MD, PhD, MBA, Hajirah N. Saeed, MD, Jeffery P. Struewing, MD, Hirohiko Sueki, MD, Chonlaphat Sukasem, BPharm, PhD, Cynthia Sung, PhD, FCP, Jason A. Trubiano, MD, Jessica Weintraub, PharmD, BCPS, Lisa M. Wheatley, MD, MPH, Kristina B. Williams, RN, BSN, Brandon Worley, MD, MSc, Wen-Hung Chung, MD, PhD, Neil H. Shear, MD, and Elizabeth J. Phillips, MD (authors); Michael Schatz, MD, MS (editor) Learning objectives:1.To identify current knowledge gaps in the clinical management of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).2.To identify key research questions and gaps pertinent to SJS/TEN.3.To discuss advances in knowledge of the genetic and mechanistic basis of SJS/TEN and their translational outputs such as pharmacogenomic screening. Recognition of Commercial Support: This CME has not received external commercial support. Disclosure of Relevant Financial Relationships with Commercial Interests: K. D. White has received research support from the National Institutes of Health (NIH). T. Beachkofsky is an Active Duty Officer in the United States Air Force. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Air Force, the Department of Defense, nor the US government. B. Carleton has received research support from the Canadian Institutes of Health Research, Canada Foundation for Innovation, Genome Canada Genome Columbia, and Provincial Health Services Authority and has received consultancy fees from AEVI Genomic Medicine. J. H. Holmes IV has stocks in Abbott Labs, Abbvie, and PermeaDerm, Inc. M. E. Lacouture has received support from Genentech and Roche. S. Mallal has Equity in IIID Ltd that holds patents for HLA-B*57:01 screening for abacavir hypersensitivity. C. M. Mitchell has received personal fees from Symbiomix Therapeutics Inc. M. Mockenhaupt has received research support from Boehringer Ingelheim, Sanofi-Aventis, Tibotec-Janssen, Grünenthal, UCB-Pharma, and BIAL; has received personal fees from Pfizer and Merck; receives royalties from UpToDate; and has served as an expert witness in legal cases of Stevens-Johnson syndrome/toxic epidermal necrolysis in the United States (last July 2016). M. Pirmohamed has received research support from the UK Medical Research Council and the International Serious Adverse Event Consortium. E. Pope has received consultancy fees from Abvvie and ProQI; has received research support from Galderma; and has received consultancy fees and research support from Pierre Fabre Pharmaceuticals. J.-C. Roujeau has received personal fees from Ipsen Menarini, Pfizer, Novartis, Clinigen, Ab-Science, and UpToDate and has been a paid expert witness for US lawyers in several cases of SJS/TEN (more than 36 months ago). H. Sueki has received research support from the Ministry of Health, Labor and Welfare of Japan. K. B. Williams has received research support from the NIH. N. H. Shear has received research support from Lilly Canada and the NIH; has received speaker fees from Takeda; and is an unpaid board member of the Canadian Stevens-Johnson Foundation. E. J. Phillips has received research support from the National Health and Medical Research Council Australia, the NIH, and ACH2 Australia; receives royalties from UpToDate; has received consultancy fees from Biocryst, Aicuris, Xcovery, and Medicines for Malaria (MMV); and is codirector of the company holding the patent for HLA-B*57:01 testing for abacavir hypersensitivity reaction. The rest of the authors declare that they have no relevant conflicts of interest. M. Schatz disclosed no relevant financial relationships. This article is a summary of a meeting that was held on March 2, 2017. You may view the presentations from the meeting and earn additional CME credit at http://www.jaci-inpractice.org/sjs-ten-2017. This article is a summary of a meeting that was held on March 2, 2017. You may view the presentations from the meeting and earn additional CME credit at http://www.jaci-inpractice.org/sjs-ten-2017.